{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:12:25Z","timestamp":1792804345355,"version":"4.5.0"},"reference-count":51,"publisher":"National Academy of Sciences","issue":"22","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"KTI-Innosuisse","award":["27679.1 PFLS-LS"],"award-info":[{"award-number":["27679.1 PFLS-LS"]}]},{"name":"NanoArgovia\/Swiss Nanoscience Institute","award":["NCTNano 14.13"],"award-info":[{"award-number":["NCTNano 14.13"]}]},{"name":"EIC Horizon 2020","award":["NEXIM - EIC-SMEInst-868342"],"award-info":[{"award-number":["NEXIM - EIC-SMEInst-868342"]}]}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2025,6,3]]},"abstract":"<jats:p>Aberrant activation and overexpression of the epidermal growth factor receptor (EGFR) occurs in various solid cancers and often correlates with poor outcome. The clinical benefit from EGFR-targeted therapies is usually short-lived, with resistance being driven by tumor heterogeneity and an immunosuppressive tumor microenvironment (TME). To address these limitations, we developed Targeted Apoptotic Immune Modulators (TAIM), a nonviral nanoparticle platform for the targeted delivery of polyinosine:polycytosine (polyIC), to simultaneously induce tumor cell death and activate antitumor immunity. The first TAIM compound, TAR001, was designed as a systemic treatment against metastatic EGFR-positive solid cancers. Here, we present TAR001\u2019s multifaceted mode of action. We demonstrate that TAR001 is selective toward EGFR-overexpressing cancers, provoking a pattern recognition response, apoptosis, cytokine secretion, and antitumor immunity. TAR001 modulates the TME, recruiting and activating both innate and adaptive immune cells. Systemic delivery of TAR001 markedly extends survival and inhibits tumor growth in multiple murine tumor models. TAR001 represents an innovative, safe, multimodal treatment approach with the potential to benefit patients with metastatic head and neck, non\u2013small cell lung cancer, colorectal, renal, and triple-negative breast cancers. This unique modality utilizes a broad range of mechanisms to overcome the tumor\u2019s ability to escape apoptosis and immune cell activation.<\/jats:p>","DOI":"10.1073\/pnas.2500489122","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T11:27:10Z","timestamp":1748518030000},"update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":5,"title":["Targeted apoptotic immune modulator for the treatment of metastatic EGFR-positive solid tumors"],"prefix":"10.1073","volume":"122","author":[{"given":"Derrick","family":"Broka","sequence":"first","affiliation":[{"name":"TargImmune Therapeutics","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, Silberman Life Sciences Institute, The Hebrew University of Jerusalem, Edmond J. Safra Campus","place":["Jerusalem, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei","family":"Shir","sequence":"additional","affiliation":[{"name":"TargImmune Therapeutics","place":["Basel, Switzerland"]},{"name":"Department of Biological Chemistry, Silberman Life Sciences Institute, The Hebrew University of Jerusalem, Edmond J. Safra Campus","place":["Jerusalem, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babette","family":"Schade","sequence":"additional","affiliation":[{"name":"TargImmune Therapeutics","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Saxena","sequence":"additional","affiliation":[{"name":"TargImmune Therapeutics","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasia","family":"Dasargyri","sequence":"additional","affiliation":[{"name":"TargImmune Therapeutics","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Jarzebinska","sequence":"additional","affiliation":[{"name":"TargImmune Therapeutics","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"De Feyter","sequence":"additional","affiliation":[{"name":"TargImmune Therapeutics","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davor","family":"Bajic","sequence":"additional","affiliation":[{"name":"TargImmune Therapeutics","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Colecchia","sequence":"additional","affiliation":[{"name":"TargImmune Therapeutics","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"D'Amico","sequence":"additional","affiliation":[{"name":"TargImmune Therapeutics","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Kitas","sequence":"additional","affiliation":[{"name":"TargImmune Therapeutics","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Hikri","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Rabin Medical Center","place":["Petah Tikva, Israel"]},{"name":"Translational Research in Head and Neck Cancer, Felsenstein Medical Research Center, Rabin Medical Center, Faculty of Medical and Health Sciences, Tel Aviv University","place":["Tel Aviv, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal Jerzy","family":"Skowicki","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Basel","place":["Basel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal Jerzy","family":"Okoniewski","sequence":"additional","affiliation":[{"name":"Scientific IT Services ID, ETH","place":["Z\u00fcrich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Baldino","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center","place":["New York"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Besnik","family":"Qeriqi","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Program, Memorial Sloan-Kettering Cancer Center","place":["New York, NY"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa de","family":"Stanchina","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Program, Memorial Sloan-Kettering Cancer Center","place":["New York, NY"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Department of Biosystems Science and Engineering, Swiss Federal Institute of Technology","place":["ETH Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Buchi","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, University of Basel and University Hospital","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-5355","authenticated-orcid":false,"given":"Cornelia G.","family":"Palivan","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Basel","place":["Basel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaakov","family":"Benenson","sequence":"additional","affiliation":[{"name":"Department of Biosystems Science and Engineering, Swiss Federal Institute of Technology","place":["ETH Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Zippelius","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, University of Basel and University Hospital","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriano","family":"Fabbro","sequence":"additional","affiliation":[{"name":"TargImmune Therapeutics","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Scaltriti","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center","place":["New York"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviram","family":"Mizrachi","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Rabin Medical Center","place":["Petah Tikva, Israel"]},{"name":"Translational Research in Head and Neck Cancer, Felsenstein Medical Research Center, Rabin Medical Center, Faculty of Medical and Health Sciences, Tel Aviv University","place":["Tel Aviv, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Levitzki","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, Silberman Life Sciences Institute, The Hebrew University of Jerusalem, Edmond J. Safra Campus","place":["Jerusalem, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Pombo-Villar","sequence":"additional","affiliation":[{"name":"TargImmune Therapeutics","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Zigler","sequence":"additional","affiliation":[{"name":"TargImmune Therapeutics","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.08.004"},{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212476"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1393-8"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00379-6"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102602"},{"key":"e_1_3_4_6_2","first-page":"PO.18.00180","article-title":"Revisiting epidermal growth factor receptor (EGFR) amplification as a target for anti-EGFR therapy: Analysis of cell-free circulating tumor DNA in patients with advanced malignancies","volume":"3","author":"Kato S.","year":"2019","unstructured":"S. Kato , Revisiting epidermal growth factor receptor (EGFR) amplification as a target for anti-EGFR therapy: Analysis of cell-free circulating tumor DNA in patients with advanced malignancies. JCO Precis. Oncol. 3, PO.18.00180 (2019).","journal-title":"JCO Precis. Oncol."},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.813732"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12155"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00231-3"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2008.03021.x"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.2587"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.117"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403614"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00195-8"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-012-1149-4"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.11-202333"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/57.3.599"},{"key":"e_1_3_4_18_2","first-page":"1645","article-title":"Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid poly-L-lysine, in carboxymethylcellulose(PoIy(ICLC)], a highly effective interferon inducer","volume":"39","author":"Levine A. S.","year":"1979","unstructured":"A. S. Levine, M. Sivulich, P. H. Wiernik, H. B. Levy, Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid poly-L-lysine, in carboxymethylcellulose(PoIy(ICLC)], a highly effective interferon inducer. Cancer Res. 39, 1645\u20131650 (1979).","journal-title":"Cancer Res."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02518-7"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq071"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb0391"},{"key":"e_1_3_4_22_2","first-page":"A1011","article-title":"Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy","volume":"9","author":"Rodas I. M.","year":"2021","unstructured":"I. M. Rodas , Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy. J. Immunother. Cancer 9, A1011\u2013A1012 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"e_1_3_4_23_2","first-page":"125","article-title":"EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice","volume":"3","author":"Shir A.","year":"2006","unstructured":"A. Shir, M. Ogris, E. Wagner, A. Levitzki, EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med. 3, 125\u2013135 (2006).","journal-title":"PLoS Med."},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-010-0225-4"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1140"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.9b00177"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2024.102506"},{"key":"e_1_3_4_28_2","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura Y.","year":"1986","unstructured":"Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387\u20136392 (1986).","journal-title":"Cancer Res."},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11060571"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202489"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1390263"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12851"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03221-2"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0568-2"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-01711-z"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01868-3"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2015.06.006"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.06.010"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax0182"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030841"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0116-z"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053422"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221148540"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09421-7"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.3001"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115015"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1340"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.4161\/onci.21542"},{"key":"e_1_3_4_51_2","first-page":"113","volume-title":"Methods in Enzymology","author":"Heideveld E.","year":"2020","unstructured":"E. Heideveld , Methods for macrophage differentiation and in vitro generation of human tumor associated-like macrophages in Methods in Enzymology, L. Galluzzi, N.-P. Rudqvist, Eds. (Academic Press Inc., 2020), vol 632, pp. 113\u2013131."}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.2500489122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T11:27:12Z","timestamp":1748518032000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/10.1073\/pnas.2500489122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":51,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025,6,3]]}},"alternative-id":["10.1073\/pnas.2500489122"],"URL":"https:\/\/doi.org\/10.1073\/pnas.2500489122","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"2025-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500489122"}}